Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human IL34 Antibodies:
anti-Mouse (Murine) IL34 Antibodies:
anti-Rat (Rattus) IL34 Antibodies:
Go to our pre-filtered search.
Mouse (Murine) Polyclonal IL34 Primary Antibody for BR, FACS - ABIN2660791
Lin, Lee, Hestir, Leo, Huang, Bosch, Halenbeck, Wu, Zhou, Behrens, Hollenbaugh, Linnemann, Qin, Wong, Chu, Doberstein, Williams: Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. in Science (New York, N.Y.) 2008
Show all 5 references for ABIN2660791
Human Monoclonal IL34 Primary Antibody for FACS - ABIN2660793
Chihara, Suzu, Hassan, Chutiwitoonchai, Hiyoshi, Motoyoshi, Kimura, Okada: IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. in Cell death and differentiation 2010
Show all 5 references for ABIN2660793
Mouse (Murine) Monoclonal IL34 Primary Antibody for BR, FACS - ABIN2665836
Covaleda, Fuller, Payne: EIAV S2 enhances pro-inflammatory cytokine and chemokine response in infected macrophages. in Virology 2010
Show all 5 references for ABIN2665836
Human Monoclonal IL34 Primary Antibody for FACS - ABIN4896347
Bézie, Picarda, Ossart, Tesson, Usal, Renaudin, Anegon, Guillonneau: IL-34 is a Treg-specific cytokine and mediates transplant tolerance. in The Journal of clinical investigation 2015
Human Monoclonal IL34 Primary Antibody for ICC, FACS - ABIN969216
Slomiany, Baker, Elliott, Grossel: Changes in motility, gene expression and actin dynamics: Cdk6-induced cytoskeletal changes associated with differentiation in mouse astrocytes. in Journal of cellular biochemistry 2006
The current study aimed to assess the IL-34 expression in response to two members of the transforming growth factor (TGF)-beta family, TGF-beta1 and bone morphogenetic protein (BMP)-2, in synovial fibroblasts from rheumatoid arthritis patients.
The receiver operating characteristic (ROC) curve analysis has shown that IL-34 has more discriminatory power than C-reactive protein (CRP (show CRP Antibodies)) for the risk of diabetic complications. The cut-off value for IL-34 was established as 91.2 pg/mL. The gist of our research was identification of IL-34 as an additional potential inflammatory biomarker for the prediction of the risk of vascular diabetic complications.
miR (show MLXIP Antibodies)-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis
findings demonstrated that M-CSF (show CSF1 Antibodies) binds to IL-34; molecular docking studies predicted the formation of a heteromeric M-CSF (show CSF1 Antibodies)/IL-34 cytokine
These results suggest that IL-34, a novel osteoclastogenic cytokine, plays a role in rheumatoid arthritis-associated joint damage and is a potential biomarker for predicting subsequent radiographic progression in patients with RA.
IL-34 is expressed by human FOXP3 (show FOXP3 Antibodies)+CD45RCloCD8+ and CD4 (show CD4 Antibodies)+ Tregs and markedly inhibited alloreactive immune responses.
This paper provides evidence of alternative binding of IL-34 to chondroitin sulphates and syndecan-1 (show SDC1 Antibodies) at the cell surface that modulates M-CSFR (show CSF1R Antibodies) activation.
In vitro and in vivo experiments indicate that IL-34 expression is regulated by TNF-a (show TNF Antibodies) and IL-1b (show IL1B Antibodies) and that its overexpression is associated with an increase in osteosarcoma growth and metastasis.
the expression pattern of IL-34 in ileum and colon and suggest IL-34 as a new modulator of inflammation in inflammatory bowel disease
IL-34 is up-regulated in inflammatory bowel disease and suggest a role for this cytokine in sustaining the inflammatory responses in this disease
study concludes that Langerhans cells require IL-34 when residing in fully differentiated and anatomically intact skin epidermis, but rely on neutrophil-derived CSF1 (show CSF1 Antibodies) during inflammation
constitutive IL-34 expressed by skin keratinocytes might suppress resident macrophage responses to C. albicans colonisation by maintaining low levels TLR2 (show TLR2 Antibodies) and Dectin-1 (show CLEC7A Antibodies) expression by macrophages.
IL-34 protected blood-brain barrier integrity by restored expression levels of tight junction proteins, which were downregulated by pro-inflammatory cytokines.
IL-34-dependent, Mo-mediated, CSF-1 (show CSF1 Antibodies) nonredundant mechanisms promote persistent ischemia-incited AKI that worsens subsequent CKD.
Tumor necrosis factor-alpha (show TNF Antibodies) induces IL-34 expression via NF-kappaB (show NFKB1 Antibodies) in MC3T3-E1 osteoblastic cells.
These findings suggest that TGF-beta (show TGFB1 Antibodies) produced by IL-34-treated microglia is a negative regulator of microglial proliferation and enhances the neuroprotective property of microglia.
Differentiated signaling between IL-34 and CSF-1 (show CSF1 Antibodies) is likely achieved by the relative thermodynamic independence of IL-34 versus negative cooperativity of CSF-1 (show CSF1 Antibodies) at the CSF-1 receptor (show CSF1R Antibodies) recognition sites.
Interleukin-34 is a cytokine that promotes the differentiation and viability of monocytes and macrophages through the colony-stimulating factor-1 receptor (CSF1R\; MIM 164770) (Lin et al., 2008